J. E. Garber

1.2k citations

26 papers · 783 indexed · h-index 9

Impact in

Genetics top 5%
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment

Papers in ⓘ

Genetics 12
- BRCA gene mutations in cancer 8
- Estrogen and related hormone effects 3
Cancer Research 6
- Breast Cancer Treatment Studies 2
- Cancer, Lipids, and Metabolism 2

Co-authors: Claudine Isaacs (2 shared papers)Susan L. Neuhausen (2 shared papers)Patrice Watson (1 shared paper)Timothy R. Rebbeck (1 shared paper)M. Daly (1 shared paper)Albert M. Levin (1 shared paper)Andrea Eisen (1 shared paper)O. Olopade (2 shared papers)
Journals: Journal of Clinical Oncology (12 papers)Cancer Research (6 papers)JNCI Journal of the National Cancer Institute (2 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)Gynecologic Oncology (1 paper)
Partner nations: United States Canada Spain

In The Last Decade

J. E. Garber

23 papers receiving 755 citations

Peers

Countries citing papers authored by J. E. Garber

Since Specialization

Citations

This map shows the geographic impact of J. E. Garber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. E. Garber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. E. Garber more than expected).

Fields of papers citing papers by J. E. Garber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. E. Garber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. E. Garber. The network helps show where J. E. Garber may publish in the future.

Co-authors

The 25 scholars most cited alongside J. E. Garber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. E. Garber Line = papers co-authored together J. E. Garber links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers JNCI Journal of the National Cancer Institute ·Timothy R. Rebbeck, Albert M. Levin, Andrea Eisen, C. Snyder, Patrice Watson, Lisa Cannon‐Albright, Claudine Isaacs, O. Olopade, J. E. Garber, A K Godwin, M. Daly, Steven A. Narod, Susan L. Neuhausen, H. T. Lynch, BL Weber	1999	464
2	Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy Journal of Clinical Oncology ·Paula D. Ryan, Nadine Tung, SJ Isakoff, Mehra Golshan, A. Richardson, Adriana Corben, Barbara L. Smith, R. S. Gelman, Eric P. Winer, J. E. Garber	2009	71
3	Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? Journal of Clinical Oncology ·Janet Audrain, Barbara K. Rimer, David Cella, J. E. Garber, Beth N. Peshkin, Jennifer Ellis, Joellen M. Schildkraut, Michael Stefanek, Victor G. Vogel, Caryn Lerman	1998	59
4	Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer JNCI Journal of the National Cancer Institute ·J. E. Garber, Susan Halabi, Sara M. Tolaney, Emma Kaplan, Laura Archer, J. N. Atkins, S. Edge, Charles L. Shapiro, L. G. Dressler, E. M. Paskett, G Kimmick, James C. Orcutt, Anthony J. Scalzo, E. Winer, Ellis Levine, N. Shahab, Nancy Berliner, (unknown)	2010	40
5	TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal of Clinical Oncology ·SJ Isakoff, Paul E. Goss, Erica L. Mayer, Tiffany A. Traina, LA Carey, Karen J. Krag, H. S. Rugo, M. C. Liu, Vered Stearns, SE Come, Darrell R. Borger, C. A. Quadrino, Dianne M. Finkelstein, J. E. Garber, Patrick J. Ryan, Eric P. Winer, Leif W. Ellisen	2011	30
6	Brief Assessment of Parents' Attitudes Toward Testing Minor Children for Hereditary Breast/Ovarian Cancer Genes: Development and Validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS) Journal of Pediatric Psychology ·Beth N. Peshkin, Tiffani A. DeMarco, J. E. Garber, Heiðdís Valdimarsdóttir, Andrea Farkas Patenaude, Katherine A. Schneider, Mark D. Schwartz, K. P. Tercyak	2008	28
7	Carcinoembryonic antigen in breast nipple aspirate fluid. PubMed ·Lenka Foretová, J. E. Garber, Norman L. Sadowsky, Sigitas Verselis, Deepa Joseph, Augusto Faria Andrade, Peter G. Gudrais, Diane Fairclough, F P Li	1998	23
8	Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? Journal of Clinical Oncology ·S. M. Domchek, Tara M. Friebel, Susan L. Neuhausen, Henry T. Lynch, CF Singer, Rosalind A. Eeles, Claudine Isaacs, NM Tung, PA Ganz, F.J. Couch, Jeffrey N. Weitzel, O. I. Olopade, Wendy S. Rubinstein, Gail E. Tomlinson, Gabriella C. Pichert, M. B. Daly, Ellen Matloff, D. Gareth Evans, J. E. Garber, Timothy R. Rebbeck	2011	16
9	P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. Cancer Research ·SJ Isakoff, Beth Overmoyer, NM Tung, RS Gelman, Karleen Habin, Jiang Qian, Vincent L. Giranda, Stacie Peacock Shepherd, J. E. Garber, LW Ellisen, EP Winer, PE Goss	2011	13
10	Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial. Journal of Clinical Oncology ·Paul E. Goss, J. N. Ingle, JE Alés-Martínez, Anthony Cheung, Rowan T. Chlebowski, Jean Wactawski‐Wende, Anne McTiernan, John Robbins, Karen Johnson, Lee Martin, Eric Winquist, Gloria E. Sarto, J. E. Garber, Carol J. Fabian, Pascal Pujol, Elizabeth Maunsell, Pierre Farmer, Karen A. Gelmon, Dongsheng Tu, Harriet Richardson	2011	7
11	Diagnosis in Oncology. Leukemia cutis. Journal of Clinical Oncology ·William C. Hahn, DT Jones, Pearl Leavitt, J. E. Garber, R. M. Stone, Arthur T. Skarin	1997	5
12	Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. Cancer Research ·SJ Isakoff, PE Goss, EL Mayer, Tiffany A. Traina, LA Carey, KJ Krag, MC Liu, Hope S. Rugo, Vered Stearns, Steven E. Come, Dianne M. Finkelstein, A-R Hartman, J. E. Garber, Patrick J. Ryan, EP Winer, LW Ellisen	2012	5
13	Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen Journal of Clinical Oncology ·J. E. Garber, Susan Halabi, Emma Kaplan, S. B. Edge, L. G. Dressler, Electra D. Paskett, Nancy Berliner	2005	4
14	Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis Cancer Research ·ML Telli, Sunil Badve, S Vinayak, DP Silver, SJ Isakoff, VG Kaklamani, WJ Gradishar, Vered Stearns, RM Connolly, JM Ford, Sylvia Adams, J. E. Garber, Brent Evans, Kirsten M. Timms, Richard Wenstrup, A. Richardson	2017	3
15	Prophylactic oophorectomies in women at high risk for ovarian cancer Gynecologic Oncology ·K. H. Lu, J. E. Garber, D. W. Cramer, Deborah Schrag, William R. Welch, Ross S. Berkowitz, Momotaro Muto	1999	2
16	Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer Journal of Clinical Oncology ·L.J. Pierce, Kathleen A. Griffith, Saundra Buys, David K. Gaffney, B. Haffty, Maggie Moran, Merav Ben‐David, J. E. Garber, Sofía D. Merajver, Amichay Meirovitz, S. M. Domchek	2008	2
17	DNA repair protein biomarkers in triple negative breast cancer. Cancer Research ·BM Alexander, Kam Sprott, X Wang, AD D'Andrea, SJ Schnitt, LC Collins, DT Weaver, J. E. Garber	2009	2
18	P27 and pAKT Expression in BRCA1-associated and sporadic breast tumors Journal of Clinical Oncology ·Anne Blackwood‐Chirchir, Maria Tretiakova, Weihong Yuan, T. Proverbs-Singh, Jeong‐Hoon Kim, Tonmoy Das, J. E. Garber, Clay Klein, O. Olopade, BL Weber	2004	2
19	Breast cancer phenotype in women with TP53 germ-line mutations: An LFS consortium effort. Journal of Clinical Oncology ·Serena Masciari, Drupadi Dillon, Michèlle Dick, Mark E. Robson, Jeffrey N. Weitzel, Jeremy Ford, Judith Balmañà, SB Gruber, David Euhus, J. E. Garber	2011	2
20	COMPELEMENTARY AND ALTERNATIVE MEDICINE USE AMANG WOMEN WITH BREAST CANCER L. Digianni, J. E. Garber	2002	1

About J. E. Garber

J. E. Garber is a scholar working on Genetics, Cancer Research, Reproductive Medicine, Oncology and Hematology, having authored 26 papers that have together received 783 indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (8 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Treatment and Pharmacology (3 papers), PARP inhibition in cancer therapy (3 papers), Ovarian cancer diagnosis and treatment (3 papers), Estrogen and related hormone effects (3 papers), Breast Cancer Treatment Studies (2 papers) and Cancer, Lipids, and Metabolism (2 papers). The work is most often cited by research in Genetics (549 citations), Reproductive Medicine (145 citations), Cancer Research (250 citations), Oncology (268 citations) and Pathology and Forensic Medicine (151 citations). J. E. Garber has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Claudine Isaacs, Susan L. Neuhausen, Patrice Watson, Timothy R. Rebbeck, M. Daly, Albert M. Levin, Andrea Eisen, O. Olopade, H. T. Lynch and BL Weber. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, JNCI Journal of the National Cancer Institute, International Journal of Radiation Oncology*Biology*Physics and Gynecologic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact